Literature DB >> 16239913

Growth factors and antiapoptotic signaling pathways in multiple myeloma.

N W C J van de Donk1, H M Lokhorst, A C Bloem.   

Abstract

Failure of myeloma cells to undergo apoptosis plays an important role in the accumulation of myeloma cells within the bone marrow (BM). Moreover, inhibition of drug-induced apoptosis has been indicated as a major contributor of drug resistance in myeloma. The BM microenvironment promotes survival and blocks the apoptotic effects of various cytotoxic agents through the production of cytokines as well as through direct physical interactions. Several antiapoptotic proteins and antiapoptotic signaling cascades have been identified that contribute to the antiapoptotic phenotype of the myeloma cell. In this review, we discuss mechanisms that result in enhanced survival and drug resistance of myeloma cells. Insight into these mechanisms is essential to make progress in the therapy of myeloma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16239913     DOI: 10.1038/sj.leu.2403970

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  15 in total

1.  RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2.

Authors:  Yuan Xiao Zhu; Hongwei Yin; Laura A Bruins; Chang-Xin Shi; Patrick Jedlowski; Meraj Aziz; Chris Sereduk; Klaus Martin Kortuem; Jessica E Schmidt; Mia Champion; Esteban Braggio; A Keith Stewart
Journal:  Blood       Date:  2014-11-13       Impact factor: 22.113

2.  Pasteurella multocida toxin-stimulated osteoclast differentiation is B cell dependent.

Authors:  Dagmar Hildebrand; Klaus Heeg; Katharina F Kubatzky
Journal:  Infect Immun       Date:  2010-10-18       Impact factor: 3.441

3.  Treatment optimization for multiple myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in in vitro and ex vivo models.

Authors:  Enrica Borsi; Marina Martello; Barbara Santacroce; Elena Zamagni; Paola Tacchetti; Lucia Pantani; Katia Mancuso; Serena Rocchi; Michele Cavo; Carolina Terragna
Journal:  Haematologica       Date:  2018-07-19       Impact factor: 9.941

4.  The small GTPase RhoA is crucial for MC3T3-E1 osteoblastic cell survival.

Authors:  Tomohiko Yoshida; Mary F Clark; Paula H Stern
Journal:  J Cell Biochem       Date:  2009-04-01       Impact factor: 4.429

5.  Platelet factor 4 induces cell apoptosis by inhibition of STAT3 via up-regulation of SOCS3 expression in multiple myeloma.

Authors:  Pei Liang; Suk Hang Cheng; Chi Keung Cheng; Kin Mang Lau; Shek Ying Lin; Eudora Y D Chow; Natalie P H Chan; Rosalina K L Ip; Raymond S M Wong; Margaret H L Ng
Journal:  Haematologica       Date:  2012-08-28       Impact factor: 9.941

Review 6.  Targeting the IGF-1R signaling and mechanisms for epigenetic gene silencing in human multiple myeloma.

Authors:  Helena Jernberg-Wiklund; Kenneth Nilsson
Journal:  Ups J Med Sci       Date:  2012-02-21       Impact factor: 2.384

7.  Drug inhibition profile prediction for NFκB pathway in multiple myeloma.

Authors:  Huiming Peng; Jianguo Wen; Hongwei Li; Jeff Chang; Xiaobo Zhou
Journal:  PLoS One       Date:  2011-03-07       Impact factor: 3.240

8.  The proportion of CD16(+)CD14(dim) monocytes increases with tumor cell load in bone marrow of patients with multiple myeloma.

Authors:  Anne M Sponaas; Siv H Moen; Nina B Liabakk; Emadoldin Feyzi; Toril Holien; Solveig Kvam; Lill Anny G Grøseth; Berit Størdal; Glenn Buene; Terje Espevik; Anders Waage; Therese Standal; Anders Sundan
Journal:  Immun Inflamm Dis       Date:  2015-03-02

9.  A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo.

Authors:  J Glauer; N Pletz; M Schön; P Schneider; N Liu; K Ziegelbauer; S Emmert; G G Wulf; M P Schön
Journal:  Blood Cancer J       Date:  2013-09-06       Impact factor: 11.037

10.  A novel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitors.

Authors:  Carolina Vicente-Dueñas; Isabel Romero-Camarero; Inés González-Herrero; Esther Alonso-Escudero; Fernando Abollo-Jiménez; Xiaoyu Jiang; Norma C Gutierrez; Alberto Orfao; Nieves Marín; Luisa María Villar; Ma Carmen Fernández Criado; Belén Pintado; Teresa Flores; Diego Alonso-López; Javier De Las Rivas; Rafael Jiménez; Francisco Javier García Criado; María Begoña García Cenador; Izidore S Lossos; César Cobaleda; Isidro Sánchez-García
Journal:  EMBO J       Date:  2012-08-17       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.